Literature DB >> 26932589

Skin cancer in patients with psoriasis.

A Egeberg1, J P Thyssen1, G H Gislason2,3,4, L Skov1.   

Abstract

BACKGROUND: Psoriasis is a chronic inflammatory skin disease that is commonly treated with ultraviolet phototherapy and systemic immunosuppressant drugs, which may confer a risk of skin cancer. Previous studies on the risk of skin cancer in patients with psoriasis have shown conflicting results.
OBJECTIVES: We investigated the risk of new-onset melanoma and non-melanoma skin cancer (NMSC), respectively, in a large cohort of patients with psoriasis and psoriatic arthritis.
METHODS: Data on all Danish individuals aged ≥18 years between 1 January 1997 and 31 December 2012 were linked at individual-level in nationwide registers. Incidence rates per 10 000 person-years were calculated, and incidence rate ratios (IRRs) were estimated by Poisson regression models.
RESULTS: The study comprised 5 559 420 individuals with a maximum follow-up time of 16 years. There were 75 410 patients with psoriasis, and 25 087 and 58 051 individuals developed melanoma and NMSC, respectively, during follow-up. Adjusted IRRs (95% CI) of melanoma were 1.19 (1.03-1.37), 1.09 (0.75-1.58) and 1.36 (0.94-1.99), in mild psoriasis, severe psoriasis and psoriatic arthritis, respectively, and the corresponding adjusted IRRs of NMSC were 1.67 (1.55-1.81), 1.32 (1.10-1.59) and 1.62 (1.27-2.05) respectively.
CONCLUSIONS: We observed a modestly increased risk of melanoma and NMSC in patients with mild psoriasis, whereas patients with severe psoriasis and psoriatic arthritis had increased risk of NMSC but not melanoma. While the risk of skin cancer is only modestly increased in patients with psoriasis, clinicians should remain vigilant.
© 2016 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2016        PMID: 26932589     DOI: 10.1111/jdv.13619

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  7 in total

Review 1.  Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.

Authors:  Shamir Geller; Haoming Xu; Mark Lebwohl; Beatrice Nardone; Mario E Lacouture; Meenal Kheterpal
Journal:  Am J Clin Dermatol       Date:  2018-06       Impact factor: 7.403

2.  Concordance and timing in recording cancer events in primary care, hospital and mortality records for patients with and without psoriasis: A population-based cohort study.

Authors:  Alex M Trafford; Rosa Parisi; Martin K Rutter; Evangelos Kontopantelis; Christopher E M Griffiths; Darren M Ashcroft
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

Review 3.  Risk of Developing Melanoma With Systemic Agents Used to Treat Psoriasis: A Review of the Literature.

Authors:  Amy Semaka; Thomas G Salopek
Journal:  J Cutan Med Surg       Date:  2021-08-15       Impact factor: 2.092

4.  Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2).

Authors:  J L W Lambert; S Segaert; P D Ghislain; T Hillary; A Nikkels; F Willaert; J Lambert; R Speeckaert
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-08-13       Impact factor: 6.166

Review 5.  The Risk of Systemic Diseases in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic.

Authors:  Yu Ri Woo; Chul Jong Park; Hoon Kang; Jung Eun Kim
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923

Review 6.  Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular Risk.

Authors:  Maria J E Visser; Gareth Tarr; Etheresia Pretorius
Journal:  Front Immunol       Date:  2021-07-16       Impact factor: 7.561

7.  A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis.

Authors:  Emmanouil Charakopoulos; Ioannis Spyrou; Nora-Athina Viniou; Nefeli Giannakopoulou; Sevastianos Hatzidavid; Panagiotis Theodorou Diamantopoulos
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.